الفهرس 
DIABETIC NEPHROPATHYOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
Abstract
Background: Food-derived compounds have been shown to have beneficial effects in type 1 diabetes mellitus (T1DM). Among these compounds, resveratrol (3,5,4′‐trihydroxystilbene) which is found in grapes, peanuts, cranberries. Resveratrol has a wide range of effects including antimicrobial, anti‐inflammatory, anti-apoptotic, anticancer, anti-oxidative and cardio-protective effects. Resveratrol is capable of inducing beneficial effects in diabetic animals and thereby, ameliorates diabetes. Recently, resveratrol showed beneficial effects in adults with T1DM.
Objectives: Therefore, we performed a randomized-controlled trial to assess the effect of oral resveratrol supplementation on glycemic control, lipid profile and kidney injury molecule-1 (KIM-1) levels in pediatric patients with T1DM and diabetic nephropathy.
Methods: This study included 60 children and adolescents with T1DM. Enrolled patients aged 12-18 years with disease duration > 5 years and have diabetic nephropathy. Patients were randomly assigned into two groups; intervention group (group A) who received oral resveratrol tablets 250 mg twice daily. The other group (group B) did not receive any supplementation and served as a control group. Both groups were followed-up for 6 months with assessment of fasting blood glucose (FBG), HbA1c, urinary albumin creatinine ratio (UACR) and KIM-1 levels. Insulin sensitivity score and estimated glucose disposal rate (eGDR) were calculated.
Results: Both groups were well-matched as regards baseline clinical characteristics and laboratory parameters (p>0.05). After 6 months, resveratrol therapy for group A resulted in a significant decrease of FBG, HbA1c, triglycerides, total cholesterol, UACR and KIM-1 levels while insulin sensitivity score and eGDR were significantly higher compared with baseline levels and compared with group B (p<0.001). No significant difference was found between T1DM patients with diabetic nephropathy without resveratrol adjuvant therapy at baseline and at 6 months as regards any of the studied clinical or laboratory data except for HbA1c, triglycerides and total cholesterol which were significantly increased at study end. Baseline KIM-1 levels were positively correlated to FBG, HbA1c, total cholesterol.
Conclusions: Resveratrol as an adjuvant therapy to insulin improved blood glucose levels, glycemic control, dyslipidemia and ameliorates diabetic nephropathy without adverse effects in pediatric patients with T1DM.